Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer

Summary

RET fusions are present in 1% to 2% of unselected population of non-small cell lung cancer (NSCLC). Existing US Food and Drug Administration-approved inhibitors of RET tyrosine kinase show promising therapeutic effects in a non-small cell lung cancer patients. Apatinib is an oral multi-kinase inhibitors including RET fusions. This study is designed to evaluate the safety and tolerability of Apatinib in patients with RET fusion positive advanced NSCLC.

Timeline

Start

2015-01

Primary completion

2016-12

Completion

2017-12

Drugs

Indications